Wayne Yakes
Englewood, CONPI 1982711503
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $1,250,167 of the $1,403,729 with a category attached, or 89.1%. Medtronic accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $1,250,173 and has fallen 100.0% since, to $187 in 2025.
Across 75 payments — averaging $18,716 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1.4M
- Stryker$1K
- Penumbra, Inc.$274
What the payments were for
- Royalty or licence$1,250,16789%
- Food & beverage$1,4100%
- Other$152,15211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 6 | $1,402,325 |
| Stryker | 66 | $1,131 |
| Penumbra, Inc. | 3 | $274 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ellipsys$1,402,319
- TARGET$166
- Penumbra Jet 7$136
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 16 | $63 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.